# The San Diego-based biotech is exploring the ‌joint spin-off of the drug, INBRX-106, and a second experimental cancer treatment.

*biotech · news · 2026-04-22 · Reuters*

## Key points

- Inhibrx is considering jointly spinning off INBRX-106 and ozekibart, potentially worth over $9 billion.
- Ozekibart has shown a 52% tumor shrinkage rate in Ewing sarcoma patients in one study.
- INBRX-106’s valuation depends on its ability to enhance Keytruda efficacy in ongoing clinical trials.
- Inhibrx is expected to announce interim INBRX-106 trial results and ozekibart FDA filing next month.
- Merck's strategic need for INBRX-106 arises as Keytruda faces 2028 patent expirations and biosimilar competition.

**Companies:** Merck, Inhibrx
**Countries:** United States, Germany

[Read the full story on Reuters](https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/)

---

Canonical: https://newsio.io/n/f70bc3b6-e552-4c30-9c6c-039f022d1f57/the-san-diego-based-biotech-is-exploring-the-joint-spin-off-of-the-drug-inbrx-10
Summarized by Newsio from Reuters. https://newsio.io/how-it-works